WEKO3
アイテム
Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation
http://hdl.handle.net/10271/00003871
http://hdl.handle.net/10271/000038719543b862-2bcd-4fa9-afc8-180739e03a89
名前 / ファイル | ライセンス | アクション |
---|---|---|
論文本文 (940.5 kB)
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-08-01 | |||||
タイトル | ||||||
タイトル | Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||
資源タイプ | doctoral thesis | |||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
その他のタイトル | ||||||
その他のタイトル | メサラジン顆粒剤は錠剤と比較してクローン病の臨床データを改善させる | |||||
言語 | ja | |||||
著者 |
田村, 智
× 田村, 智 |
|||||
書誌情報 |
en : Scientific Reports 巻 10, p. 21353, 発行日 2020-12-07 |
|||||
出版者 | ||||||
出版者 | Springer Nature | |||||
言語 | en | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | Copyright The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn’s disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at our facility among patients with Crohn’s disease in remission. We investigated the rate of continuous treatment of mesalazine granules and examined the changes in Crohn’s Disease Activity Index (CDAI) and serum C-reactive protein (CRP), albumin, and hemoglobin (Hb) levels 2 years after the switch. Compliance rate (continuous treatment vs. additional treatment) and continuous treatment rate [good (rate of ≥70%) vs. poor (rate<70%)] were investigated. Of 46 patients, 12 (27.3%) received additional treatment and 32 (72.7%) did not require additional treatment in 2 years. No significant change in CDAI after switching to granule modification was noted in 32 patients in the continuous treatment group. Nevertheless, clinical remission was maintained for 2 years, and serum CRP levels decreased significantly (P=0.023) and Hb levels increased significantly (P=0.002). No change in the compliance rate was found. Our results suggest that mesalazine granule formulation may have a remission maintenance effect that is superior to that of mesalazine tablets. | |||||
言語 | en | |||||
学位名 | ||||||
言語 | ja | |||||
学位名 | 博士(医学) | |||||
学位の区分 | ||||||
内容記述タイプ | Other | |||||
内容記述 | doctoral | |||||
言語 | en | |||||
学位の分野 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 医学系研究科 | |||||
言語 | ja | |||||
学位授与機関 | ||||||
学位授与機関識別子Scheme | kakenhi | |||||
学位授与機関識別子 | 13802 | |||||
言語 | ja | |||||
学位授与機関名 | 浜松医科大学 | |||||
学位授与年月日 | ||||||
学位授与年月日 | 2021-03-16 | |||||
学位授与番号 | ||||||
学位授与番号 | 甲第862号 | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 2045-2322 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 33288852 | |||||
出版社DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1038/s41598-020-78603-9 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |